Today announced completion of a $13 million Series C funding.

CeNeRx BioPharma raises $13 million through Series C funding to support TriRima Phase II trial CeNeRx BioPharma, Inc., a clinical stage business developing and commercializing innovative treatments for diseases of the central anxious program , today announced completion of a $13 million Series C funding. ‘These funds will support the Stage II trial of TriRima as monotherapy for treatment-resistant despair,’ said Barry Brand, CEO of CeNeRx.’ Related StoriesEstradiol fluctuation may enhance emotional sensitivity to psychosocial tension during menopausal transitionUCLA launches second Grand Challenge to reduce health and financial impacts of depressionComputerised cognitive behavioural therapy likely to be ineffective in depressive disorder treatmentCeNeRx is preparing to conduct a Phase II trial with an improved formulation of its business lead product applicant TriRima for treatment-resistant melancholy..There exists a motion to get Caution labels, such as for example those on cigarettes, put into soft drinks. Additionally, there are individuals who want to taxes the beverages both to create them less obtainable and move them back again to luxury-like status, aswell as to fund the treating medical problems they create, again, like smokes. Some individuals also want sodas taken off all children’s menus. It isn’t information that soda is harmful to you. How lousy may be a little bit of surprise Just. The problem is, many of us don’t need to know.